These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23106932)

  • 41. Symptomatic remission and neurocognitive functioning in patients with schizophrenia.
    Hofer A; Bodner T; Kaufmann A; Kemmler G; Mattarei U; Pfaffenberger NM; Rettenbacher MA; Trebo E; Yalcin N; Fleischhacker WW
    Psychol Med; 2011 Oct; 41(10):2131-9. PubMed ID: 21426601
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Attention/vigilance in schizophrenia: performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS).
    Nuechterlein KH; Green MF; Calkins ME; Greenwood TA; Gur RE; Gur RC; Lazzeroni LC; Light GA; Radant AD; Seidman LJ; Siever LJ; Silverman JM; Sprock J; Stone WS; Sugar CA; Swerdlow NR; Tsuang DW; Tsuang MT; Turetsky BI; Braff DL
    Schizophr Res; 2015 Apr; 163(1-3):38-46. PubMed ID: 25749017
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects.
    Altshuler LL; Ventura J; van Gorp WG; Green MF; Theberge DC; Mintz J
    Biol Psychiatry; 2004 Oct; 56(8):560-9. PubMed ID: 15476685
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
    Liu F; Guo X; Wu R; Ou J; Zheng Y; Zhang B; Xie L; Zhang L; Yang L; Yang S; Yang J; Ruan Y; Zeng Y; Xu X; Zhao J
    Schizophr Res; 2014 Mar; 153(1-3):169-76. PubMed ID: 24503176
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An investigation of 3 neurocognitive subtypes in schizophrenia.
    Ammari N; Heinrichs RW; Miles AA
    Schizophr Res; 2010 Aug; 121(1-3):32-8. PubMed ID: 20646913
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First-episode schizophrenia patients neuropsychologically within the normal limits: evidence of deterioration in speed of processing.
    González-Blanch C; Rodríguez-Sánchez JM; Pérez-Iglesias R; Pardo-García G; Martínez-García O; Vázquez-Barquero JL; Crespo-Facorro B
    Schizophr Res; 2010 Jun; 119(1-3):18-26. PubMed ID: 20335007
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic.
    Kitajima R; Miyamoto S; Tenjin T; Ojima K; Ogino S; Miyake N; Fujiwara K; Funamoto Y; Arai J; Tsukahara S; Ito Y; Tadokoro M; Anai K; Kaneda Y; Yamaguchi N
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):300-6. PubMed ID: 22122880
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cognitive reserve as a predictor of two year neuropsychological performance in early onset first-episode schizophrenia.
    de la Serna E; Andrés-Perpiñá S; Puig O; Baeza I; Bombin I; Bartrés-Faz D; Arango C; Gonzalez-Pinto A; Parellada M; Mayoral M; Graell M; Otero S; Guardia J; Castro-Fornieles J
    Schizophr Res; 2013 Jan; 143(1):125-31. PubMed ID: 23182439
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlation between insight dimensions and cognitive functions in patients with deficit and nondeficit schizophrenia.
    Pegoraro LFL; Dantas CR; Banzato CEM; Fuentes D
    Schizophr Res; 2013 Jun; 147(1):91-94. PubMed ID: 23535076
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia.
    Kontis D; Theochari E; Kleisas S; Kalogerakou S; Andreopoulou A; Psaras R; Makris Y; Karouzos C; Tsaltas E
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1333-41. PubMed ID: 20691745
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term course of cognitive function in chronically hospitalized patients with schizophrenia transitioning to community-based living.
    Nemoto T; Niimura H; Ryu Y; Sakuma K; Mizuno M
    Schizophr Res; 2014 May; 155(1-3):90-5. PubMed ID: 24725850
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cognitive deficit awareness in schizophrenia: absent, intact, or somewhere in-between?
    Balzan RP; Neaves A; Denson LA; Liu D; Galletly C
    Cogn Neuropsychiatry; 2014; 19(6):471-84. PubMed ID: 24749790
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reduction of cortical GABAergic inhibition correlates with working memory impairment in recent onset schizophrenia.
    Takahashi S; Ukai S; Kose A; Hashimoto T; Iwatani J; Okumura M; Tsuji T; Shinosaki K
    Schizophr Res; 2013 May; 146(1-3):238-43. PubMed ID: 23523695
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder.
    Smith RC; Lindenmayer JP; Davis JM; Cornwell J; Noth K; Gupta S; Sershen H; Lajtha A
    Schizophr Res; 2009 May; 110(1-3):149-55. PubMed ID: 19251401
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Determinants of work outcome in schizophrenia and schizoaffective disorder: role of cognitive function.
    Kaneda Y; Jayathilak K; Meltzer HY
    Psychiatry Res; 2009 Sep; 169(2):178-9. PubMed ID: 19646764
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neurocognitive individualized training versus social skills individualized training: a randomized trial in patients with schizophrenia.
    Bucci P; Piegari G; Mucci A; Merlotti E; Chieffi M; De Riso F; De Angelis M; Di Munzio W; Galderisi S
    Schizophr Res; 2013 Oct; 150(1):69-75. PubMed ID: 23962828
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
    Mishara AL; Goldberg TE
    Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative study of neurocognitive function in euthymic bipolar patients and stabilized schizophrenic patients.
    Sánchez-Morla EM; Barabash A; Martínez-Vizcaíno V; Tabarés-Seisdedos R; Balanzá-Martínez V; Cabranes-Díaz JA; Baca-Baldomero E; Gómez JL
    Psychiatry Res; 2009 Oct; 169(3):220-8. PubMed ID: 19758705
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance.
    Brissos S; Dias VV; Balanzá-Martinez V; Carita AI; Figueira ML
    Schizophr Res; 2011 Jul; 129(2-3):133-6. PubMed ID: 21514793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia.
    Xavier RM; Pan W; Dungan JR; Keefe RSE; Vorderstrasse A
    Schizophr Res; 2018 Mar; 193():83-90. PubMed ID: 28693755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.